title: African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians.
abstract: African Americans as a group have a higher incidence of chronic hepatitis C (CHC) than Caucasians but are often under-represented in clinical trials used to define response rates to interferon therapy. The aim of this study was to compare African Americans with Caucasians with respect to end-of-treatment response to interferon. This retrospective study had 61 African Americans and 49 Caucasians with CHC. All patients were treated for at least 12 weeks with interferon-alpha2b (Intron A) thrice weekly. End-of-treatment response was defined as three consecutive nondetectable HCV RNA measurements at least 1 month apart. Sustained response was defined as a negative serum HCV RNA 6 months after end of treatment. Of the 110 patients, 19 achieved an end-of-treatment response (17%) but only four achieved a sustained response (4/110=4%). Of the patients achieving a sustained response, one was genotype 1 (male Caucasian), three were genotype 2/3 with four patients having no follow-up information. The end-of-treatment response was 7% for patients with genotype 1 and 71% for genotype non-1 (P < 0.005 for genotype non-1). The end-of-treatment response was significantly higher in Caucasians (14/49=31%) compared with African Americans (5/61=8%; P < 0.05). A lower response rate in African Americans with genotype 1 in contrast to Caucasians was the primary reason for the difference in end-of-treatment response (1/45=2% vs. 5/33=15%, P < 0.05). Hence, interferon treatment resulted in a poor sustained response rate in the group of patients representative of the urban populations with the highest prevalence of hepatitis C. A genotype other than type 1 was the strongest predictor of end-of-treatment response in patients treated but over 86% of patients in this urban clinic were genotype 1. Caucasians were more likely to respond than African Americans, especially in patients with genotype 1.
authors.affiliation: Division of Gastroenterology, Wayne State University School of Medicine, Detroit, MI 48201, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Kinzie
authors.forename: P H
authors.initials: PH
authors.lastname: Naylor
authors.forename: M G
authors.initials: MG
authors.lastname: Nathani
authors.forename: R R
authors.initials: RR
authors.lastname: Peleman
authors.forename: M N
authors.initials: MN
authors.lastname: Ehrinpreis
authors.forename: M
authors.initials: M
authors.lastname: Lybik
authors.forename: J R
authors.initials: JR
authors.lastname: Turner
authors.forename: J J
authors.initials: JJ
authors.lastname: Janisse
authors.forename: M
authors.initials: M
authors.lastname: Massanari
authors.forename: M G
authors.initials: MG
authors.lastname: Mutchnick
mesh_terms: D000328:Adult; D001741:Black or African American; D044383:Black People; D002908:Chronic Disease; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012367:RNA, Viral / Q000032:analysis; D012189:Retrospective Studies; D014481:United States; D044465:White People
chemical_list: D012367:RNA, Viral; D007372:Interferons